Clinical research hotspots on adenocarcinoma of esophagogastric junction

Despite increasing incidence of adenocarcinoma of esophagogastric junction (AEG) in developed countries, the optimal therapeutic approach for locally advanced disease remains controversial. Surgery is still the primary treatment for resectable AEG, surgical strategies of AEG are selected according to Siewert classification, but outcomes are dismal with surgery alone. Although multidisciplinary therapy can improve the survival of patients, there is a significant difference in the specific practices among the different regions. Perioperative chemotherapy is the standard method in most European countries, whereas preoperative chemoradiotherapy is favored in the United States. Further studies focusing on AEG are needed to determine the optimal therapeutic strategy and the ideal sequence of chemotherapy and radiation with respect to surgery, and to clarify the role of emerging targeted therapies in resectable AEG.